NO20084919L - Oksadiazolidindionforbindelse - Google Patents

Oksadiazolidindionforbindelse

Info

Publication number
NO20084919L
NO20084919L NO20084919A NO20084919A NO20084919L NO 20084919 L NO20084919 L NO 20084919L NO 20084919 A NO20084919 A NO 20084919A NO 20084919 A NO20084919 A NO 20084919A NO 20084919 L NO20084919 L NO 20084919L
Authority
NO
Norway
Prior art keywords
agent
oxadiazolidinedione
insulin secretion
compound
treatment
Prior art date
Application number
NO20084919A
Other languages
English (en)
Inventor
Norio Asai
Fumiyoshi Iwasaki
Toshio Kurosaki
Kei Ohnuki
Yasuhiro Yonetoku
Kenji Negoro
Shigeru Yoshida
Takatoshi Soga
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of NO20084919L publication Critical patent/NO20084919L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

[Problem] En forbindelse som kan anvendes som et farmasøytisk middel, nærmere bestemt et middel for fremming av insulinsekresj on eller et middel for forebyggelse/behandling av sykdom i hvilken GPR40 inngår, f.eks. diabetes eller lignende, tilveiebringes. [Måter å løse problemet på] Det ble funnet at en oksadiazolidindionfor-bindelse som særpreges ved at den besitter en benzylsubstituent eller lignende som er bundet til den sykliske gruppen via en linker i 2-posisj on i oksadiazolidindion-ringen, eller et farmasøytisk akseptabelt salt derav, har utmerket GPR4 0-agonistisk virkning. Da oksadiazolidindionforbindelsen ifølge foreliggende oppfinnelse viste utmerket fremmende virkning på insulinsekresjon og reduserende virkning på glukosenivået i blodet, er den i tillegg anvendbar som et middel for fremming av insulin-sekresjon eller et middel for forebyggelse/behandling av diabetes.
NO20084919A 2006-04-24 2008-11-21 Oksadiazolidindionforbindelse NO20084919L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006118630 2006-04-24
PCT/JP2007/058694 WO2007123225A1 (ja) 2006-04-24 2007-04-23 オキサジアゾリジンジオン化合物

Publications (1)

Publication Number Publication Date
NO20084919L true NO20084919L (no) 2009-01-20

Family

ID=38625122

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084919A NO20084919L (no) 2006-04-24 2008-11-21 Oksadiazolidindionforbindelse

Country Status (17)

Country Link
US (1) US7968552B2 (no)
EP (1) EP2011788A4 (no)
JP (1) JP5309991B2 (no)
KR (1) KR20090005208A (no)
CN (1) CN101426775B (no)
AR (1) AR060628A1 (no)
AU (1) AU2007241759B2 (no)
BR (1) BRPI0710531A2 (no)
CA (1) CA2650124A1 (no)
MX (1) MX2008013660A (no)
NO (1) NO20084919L (no)
NZ (1) NZ572146A (no)
RU (1) RU2440994C2 (no)
TW (1) TW200815377A (no)
UA (1) UA94455C2 (no)
WO (1) WO2007123225A1 (no)
ZA (1) ZA200808639B (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
AU2006291234A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
EP2222639A1 (en) * 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
JP2011515341A (ja) 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
CA2779398A1 (en) 2009-10-30 2011-05-05 Mochida Phamaceutical Co., Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
AU2010336225A1 (en) 2009-12-25 2012-08-16 Mochida Pharmaceutical Co.,Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012123449A1 (en) * 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
BR112013027883A2 (pt) 2011-04-27 2017-08-08 Mochida Pharm Co Ltd novo derivado de 1-óxido de 3-hidroxiisotiazol
WO2012147516A1 (ja) 2011-04-28 2012-11-01 持田製薬株式会社 環状アミド誘導体
WO2012150208A1 (de) 2011-05-04 2012-11-08 Bayer Cropscience Ag Verwendung von substituierten benzylalkoholestern der cyclopropancarbonsäure zur bekämpfung von insektizid-resistenten insekten
WO2012150221A2 (de) 2011-05-04 2012-11-08 Bayer Cropscience Ag Neue halogenierte benzylalkoholester der cyclopropancarbonsäure als schädlingsbekämpfungsmittel
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
CA2878695A1 (en) * 2012-07-25 2014-01-30 University Of Cincinnati Method of treating type i diabetes using apolipoprotein aiv
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2911655A1 (en) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2 kinase inhibitors for preventing or treating diabetes and for promoting -cell survival
CN103864754B (zh) * 2012-12-10 2016-12-21 中国科学院上海药物研究所 五元唑类杂环化合物及其制备方法、药物组合物和用途
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
ES2709195T3 (es) 2013-02-28 2019-04-15 Tiumbio Co Ltd Compuesto tricíclico y uso del mismo
US9776962B2 (en) * 2013-08-09 2017-10-03 Takeda Pharmaceutical Company Limited Aromatic compounds with GPR40 agonistic activity
BR112016004194A8 (pt) * 2013-09-04 2020-02-11 Bristol Myers Squibb Co compostos úteis como imunomoduladores
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2014372114A1 (en) 2013-11-14 2016-06-09 Cadila Healthcare Limited Novel heterocyclic compounds
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
US10745382B2 (en) * 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
US10590105B2 (en) * 2016-07-08 2020-03-17 Bristol-Meyers Squibb Company 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3558970B1 (en) 2016-12-20 2021-09-01 Bristol-Myers Squibb Company Compounds useful as immunomodulators
KR20190133714A (ko) 2017-03-27 2019-12-03 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 치환된 이소퀴놀린 유도체
EP3709995A4 (en) 2017-11-16 2021-04-14 Merck Sharp & Dohme Corp. BICYCLIC ANTIDIABETIC COMPOUNDS
KR20200111738A (ko) 2018-01-23 2020-09-29 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 2,8-디아실-2,8-디아자스피로[5.5]운데칸 화합물
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3759093B1 (en) 2018-03-01 2022-11-30 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3266625B2 (ja) 1991-08-15 2002-03-18 王子タック株式会社 紫外線遮蔽フィルムの製造方法
JPH072848A (ja) 1993-04-23 1995-01-06 Sankyo Co Ltd モルホリンおよびチオモルホリン誘導体
ATE174593T1 (de) * 1993-04-30 1999-01-15 Yamanouchi Pharma Co Ltd Neue bisoxadiazolidinderivate
JPH0730664A (ja) 1993-07-08 1995-01-31 Nippon Telegr & Teleph Corp <Ntt> 音声ダイヤル方式
JP3762607B2 (ja) 1993-08-09 2006-04-05 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
US5480896A (en) * 1994-01-27 1996-01-02 American Home Products Corporation Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
US5420146A (en) * 1994-05-10 1995-05-30 American Home Products Corporation Di-oxadiazolidine derivatives as antihyperglycemic agents
JPH0859638A (ja) * 1994-08-26 1996-03-05 Yamanouchi Pharmaceut Co Ltd 新規なヘテロ環誘導体又はその塩
JPH0941097A (ja) 1995-07-28 1997-02-10 Nisshin Steel Co Ltd 吸収式冷暖房機機用オーステナイト系ステンレス鋼
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
WO1997041097A2 (en) * 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
SE9702305D0 (sv) * 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
CN1735408A (zh) * 2002-11-08 2006-02-15 武田药品工业株式会社 受体机能调节剂
US7960369B2 (en) * 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
FR2857347B1 (fr) 2003-07-10 2005-09-16 Doris Engineering Terminal flottant de chargement/dechargement de navires tels que des methaniers
JP2005063729A (ja) 2003-08-08 2005-03-10 Takao Makabe 静電気被災防止マット
JP2005063725A (ja) 2003-08-08 2005-03-10 Fujitsu Hitachi Plasma Display Ltd フラットパネルディスプレイの製造方法
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
RU2006126978A (ru) * 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
CN1946666A (zh) * 2004-02-27 2007-04-11 埃姆艮股份有限公司 用于治疗代谢性疾病的化合物、药物组合物和方法
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体

Also Published As

Publication number Publication date
TW200815377A (en) 2008-04-01
RU2008146088A (ru) 2010-05-27
US20090186909A1 (en) 2009-07-23
RU2440994C2 (ru) 2012-01-27
WO2007123225A1 (ja) 2007-11-01
KR20090005208A (ko) 2009-01-12
AR060628A1 (es) 2008-07-02
BRPI0710531A2 (pt) 2012-06-19
CN101426775B (zh) 2012-10-31
CA2650124A1 (en) 2007-11-01
AU2007241759B2 (en) 2012-05-17
JP5309991B2 (ja) 2013-10-09
UA94455C2 (en) 2011-05-10
EP2011788A4 (en) 2010-10-13
JPWO2007123225A1 (ja) 2009-09-10
AU2007241759A1 (en) 2007-11-01
EP2011788A1 (en) 2009-01-07
CN101426775A (zh) 2009-05-06
MX2008013660A (es) 2008-11-10
NZ572146A (en) 2010-09-30
ZA200808639B (en) 2009-12-30
US7968552B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
NO20084919L (no) Oksadiazolidindionforbindelse
CY1119582T1 (el) Υδατικα παρασκευασματα ινσουλινης, που περιεχουν μεθειονινη
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
NO20083026L (no) Terapeutisk middel for diabetes
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
NO20092471L (no) Karboksylsyrederivat
NO20072542L (no) Pyrimidinderivat kondensert med ikke-aromatisk ring
WO2009054423A1 (ja) オキサジアゾリジンジオン化合物
WO2011159067A3 (en) Thiazole derivatives as sglt2 inhibitors and pharmaceutical composition comprising same
PH12019501251A1 (en) Novel phenyl propionic acid derivatives and uses thereof
EA021275B9 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
DOP2011000047A (es) Agentes terapeuticos 414
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
CY1117603T1 (el) Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2
NO20065122L (no) 1,1&#39;-(1,2-etyndiyl)bis-benzenderivater som PTP 1-B-hemmere
NO20065453L (no) Fenoksyalkykarboksylsyrederivater i behandlingen av inflammatoriske sykdommer.
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
WO2016060517A3 (ko) 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
WO2009133099A3 (en) Insulin precursors for oral diabetes treatment
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
NZ603614A (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
AU2012366182A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein A-IV
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application